Winton Group’s Caris Life Sciences CAI Stock Holding History

Winton Group’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-44,981	Closed	-$1.2M	–	1096
2025 Q2	$1.2M	Buy	+44,981	New	+$1.21M	0.06%	371

Other funds holding CAI

SSP

Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Winton Group's CAI Position: Q3 2025 in Review

Winton Group sold out of Caris Life Sciences (CAI) in Q3 2025, closing a stake of 44,981 shares — an estimated $1.2M sold.

Winton Group first reported a position in CAI in Q2 2025 and held it in 1 quarter. The position peaked at $1.2M in Q2 2025. 138 funds tracked by Wall St. Rank hold CAI as of Q3 2025.

Winton Group reported no remaining Caris Life Sciences position as of Q3 2025 after selling out during the quarter.
Winton Group sold 44,981 Caris Life Sciences shares in Q3 2025, an estimated $1.2M.
Winton Group first reported a position in Caris Life Sciences in Q2 2025 and held it in 1 quarter.
Winton Group's Caris Life Sciences position peaked at $1.2M in Q2 2025.
138 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.